Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.
Harrington, P. and Lucey, D. and O’Brien, K. and Jordan, K. and Moran, P. and Marshall, L. and Wilbacher, I. and Gloeckner, L. (2019): C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections. EUnetHTA-Report . HTA-Projektbericht 116.
Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.
Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.
Kisser, A. and Zechmeister-Koss, I. (2013): P16/Ki-67 Dual Stain in the triage of PAPIII/IIID cytology in cervical cancer screening . HTA-Projektbericht 72.
Mad, P. and Domanovits, H. and Fazelnia, C. and Stiassny, K. (2007): Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. QJM: An International Journal of Medicine 100 (4): 203-210.
Nachtnebel, A. (2012): Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer. DSD: Horizon Scanning in Oncology 31.
Wild, C. (2013): Repair of cartilage defects via matrix-associated autologous chondrocyte immigration. Decision Support Document 66.
Wild, C. (2003): [Troponin testing in acute coronary syndromes]. HTA-Newsletter 18: 4.
Wild, C. (2002): [Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes]. HTA-Newsletter 13: 2-3.